Reuters logo
3 个月前
BRIEF-Fortress Biotech announces final patient dosed in phase 1B trial of cael-101
2017年5月4日 / 下午12点36分 / 3 个月前

BRIEF-Fortress Biotech announces final patient dosed in phase 1B trial of cael-101

1 分钟阅读

May 4 (Reuters) - Fortress Biotech Inc:

* Fortress Biotech announces final patient dosed in phase 1b trial of cael-101 for the treatment of al amyloidosis

* Expects to readout preliminary phase 1B data mid-2017, and full data by end of year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below